George Eldridge - Aerovate Therapeutics CFO Treasurer
| AVTE Stock | USD 2.52 0.02 0.80% |
Insider
George Eldridge is CFO Treasurer of Aerovate Therapeutics
| Age | 62 |
| Address | 930 Winter Street, Waltham, MA, United States, 02451 |
| Phone | 617 443 2400 |
| Web | https://aerovatetx.com |
George Eldridge Latest Insider Activity
Tracking and analyzing the buying and selling activities of George Eldridge against Aerovate Therapeutics stock is an integral part of due diligence when investing in Aerovate Therapeutics. George Eldridge insider activity provides valuable insight into whether Aerovate Therapeutics is net buyers or sellers over its current business cycle. Note, Aerovate Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Aerovate Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
George Eldridge over a month ago Disposition of 12495 shares by George Eldridge of Aerovate Therapeutics at 31.2291 subject to Rule 16b-3 | ||
George Eldridge over six months ago Disposition of 2016 shares by George Eldridge of Aerovate Therapeutics at 2.14 subject to Rule 16b-3 | ||
George Eldridge over a year ago Disposition of 114 shares by George Eldridge of Aerovate Therapeutics at 25.0 subject to Rule 16b-3 |
Aerovate Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.4488) % which means that it has lost $0.4488 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7491) %, meaning that it created substantial loss on money invested by shareholders. Aerovate Therapeutics' management efficiency ratios could be used to measure how well Aerovate Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of March 22, 2025, Return On Tangible Assets is expected to decline to -0.91. In addition to that, Return On Capital Employed is expected to decline to -1.02. At present, Aerovate Therapeutics' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 3.1 M, whereas Total Current Assets are forecasted to decline to about 96.4 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Scott Anderson | Anebulo Pharmaceuticals | N/A | |
| Peter MD | Acrivon Therapeutics, Common | 62 | |
| Jesper Olsen | Acrivon Therapeutics, Common | N/A | |
| James Goding | Opthea | N/A | |
| MAICD MAICD | Opthea | 48 | |
| Guizhong Liu | Adagene | 54 | |
| Kristina Masson | Acrivon Therapeutics, Common | 44 | |
| Jc MD | Adagene | 60 | |
| Annie Lee | Opthea | N/A | |
| Ian Leitch | Opthea | 61 | |
| Michael Alley | AN2 Therapeutics | N/A | |
| Qinghai Zhao | Adagene | 64 | |
| Paul MD | AN2 Therapeutics | 54 | |
| Eric Devroe | Acrivon Therapeutics, Common | 46 | |
| LLM JD | Rezolute | 63 | |
| Man MBA | Adagene | 48 | |
| Josh Eizen | AN2 Therapeutics | N/A | |
| Kenneth Cundy | Anebulo Pharmaceuticals | 66 | |
| MD FACP | AN2 Therapeutics | 77 | |
| Rex CFA | Anebulo Pharmaceuticals | 64 | |
| Sanjay Chanda | AN2 Therapeutics | 60 | |
Management Performance
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.45 |
Aerovate Therapeutics Leadership Team
Elected by the shareholders, the Aerovate Therapeutics' board of directors comprises two types of representatives: Aerovate Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aerovate. The board's role is to monitor Aerovate Therapeutics' management team and ensure that shareholders' interests are well served. Aerovate Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aerovate Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Timothy Pigot, VP Commercial | ||
| Sanjeev Khindri, Executive Development | ||
| Benjamin Dake, President, Founder | ||
| Timothy MBA, CEO Director | ||
| Marinus Verwijs, Chief Officer | ||
| Stephen Yu, Senior Quality | ||
| BSc MD, Senior Development | ||
| Hunter MD, Chief Officer | ||
| MBA MR, Chief Officer | ||
| Susan Fischer, Executive Operations | ||
| Donna Dea, Head Affairs | ||
| George Eldridge, CFO Treasurer |
Aerovate Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aerovate Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.45 | ||||
| Current Valuation | (14.86 M) | ||||
| Shares Outstanding | 28.98 M | ||||
| Shares Owned By Insiders | 0.01 % | ||||
| Shares Owned By Institutions | 99.99 % | ||||
| Number Of Shares Shorted | 4.12 M | ||||
| Price To Earning | 0.64 X | ||||
| Price To Book | 0.91 X | ||||
| EBITDA | (81.31 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aerovate Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Aerovate Stock refer to our How to Trade Aerovate Stock guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aerovate Therapeutics. If investors know Aerovate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aerovate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Aerovate Therapeutics is measured differently than its book value, which is the value of Aerovate that is recorded on the company's balance sheet. Investors also form their own opinion of Aerovate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aerovate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aerovate Therapeutics' market value can be influenced by many factors that don't directly affect Aerovate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aerovate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aerovate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aerovate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.